162 related articles for article (PubMed ID: 12570822)
1. Anti-interleukin-6 therapy for Crohn's disease.
Ito H
Curr Pharm Des; 2003; 9(4):295-305. PubMed ID: 12570822
[TBL] [Abstract][Full Text] [Related]
2. IL-6 and Crohn's disease.
Ito H
Curr Drug Targets Inflamm Allergy; 2003 Jun; 2(2):125-30. PubMed ID: 14561164
[TBL] [Abstract][Full Text] [Related]
3. Novel therapy for Crohn's disease targeting IL-6 signalling.
Ito H
Expert Opin Ther Targets; 2004 Aug; 8(4):287-94. PubMed ID: 15268624
[TBL] [Abstract][Full Text] [Related]
4. IL-6 is required for the development of Th1 cell-mediated murine colitis.
Yamamoto M; Yoshizaki K; Kishimoto T; Ito H
J Immunol; 2000 May; 164(9):4878-82. PubMed ID: 10779797
[TBL] [Abstract][Full Text] [Related]
5. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo.
Atreya R; Mudter J; Finotto S; Müllberg J; Jostock T; Wirtz S; Schütz M; Bartsch B; Holtmann M; Becker C; Strand D; Czaja J; Schlaak JF; Lehr HA; Autschbach F; Schürmann G; Nishimoto N; Yoshizaki K; Ito H; Kishimoto T; Galle PR; Rose-John S; Neurath MF
Nat Med; 2000 May; 6(5):583-8. PubMed ID: 10802717
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of the effects of anti-IL-6 receptor mAb and anti-TNF mAb treatment on CD4+ T-cell responses in murine colitis.
Terabe F; Fujimoto M; Serada S; Shinzaki S; Iijima H; Tsujii M; Hayashi N; Nomura S; Kawahata H; Jang MH; Miyasaka M; Mihara M; Ohsugi Y; Kishimoto T; Naka T
Inflamm Bowel Dis; 2011 Feb; 17(2):491-502. PubMed ID: 20602470
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Crohn's disease with anti-IL-6 receptor antibody.
Ito H
J Gastroenterol; 2005 Mar; 40 Suppl 16():32-4. PubMed ID: 15902961
[TBL] [Abstract][Full Text] [Related]
8. Pathogenic role of interleukin-6 in the development of sepsis. Part II: Significance of anti-interleukin-6 and anti-soluble interleukin-6 receptor-alpha antibodies in a standardized murine contact burn model.
Pallua N; Low JF; von Heimburg D
Crit Care Med; 2003 May; 31(5):1495-501. PubMed ID: 12771624
[TBL] [Abstract][Full Text] [Related]
9. Anti-IL-6 receptor monoclonal antibody inhibits leukocyte recruitment and promotes T-cell apoptosis in a murine model of Crohn's disease.
Ito H; Hirotani T; Yamamoto M; Ogawa H; Kishimoto T
J Gastroenterol; 2002 Nov; 37 Suppl 14():56-61. PubMed ID: 12572867
[TBL] [Abstract][Full Text] [Related]
10. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.
Nakahara H; Song J; Sugimoto M; Hagihara K; Kishimoto T; Yoshizaki K; Nishimoto N
Arthritis Rheum; 2003 Jun; 48(6):1521-9. PubMed ID: 12794819
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
Mihara M; Kasutani K; Okazaki M; Nakamura A; Kawai S; Sugimoto M; Matsumoto Y; Ohsugi Y
Int Immunopharmacol; 2005 Nov; 5(12):1731-40. PubMed ID: 16102523
[TBL] [Abstract][Full Text] [Related]
12. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17.
Hashizume M; Hayakawa N; Mihara M
Rheumatology (Oxford); 2008 Nov; 47(11):1635-40. PubMed ID: 18786965
[TBL] [Abstract][Full Text] [Related]
13. Profile of soluble cytokine receptors in Crohn's disease.
Gustot T; Lemmers A; Louis E; Nicaise C; Quertinmont E; Belaiche J; Roland S; Van Gossum A; Devière J; Franchimont D
Gut; 2005 Apr; 54(4):488-95. PubMed ID: 15753533
[TBL] [Abstract][Full Text] [Related]
14. Soluble interleukin-6 receptor alpha inhibits the cytokine-Induced fractalkine/CX3CL1 expression in human vascular endothelial cells in culture.
Matsumiya T; Imaizumi T; Fujimoto K; Cui X; Shibata T; Tamo W; Kumagai M; Tanji K; Yoshida H; Kimura H; Satoh K
Exp Cell Res; 2001 Sep; 269(1):35-41. PubMed ID: 11525637
[TBL] [Abstract][Full Text] [Related]
15. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model.
Matsumoto S; Hara T; Mitsuyama K; Yamamoto M; Tsuruta O; Sata M; Scheller J; Rose-John S; Kado S; Takada T
J Immunol; 2010 Feb; 184(3):1543-51. PubMed ID: 20042582
[TBL] [Abstract][Full Text] [Related]
16. The IL-6/sIL-6R complex as a novel target for therapeutic approaches.
Rose-John S; Waetzig GH; Scheller J; Grötzinger J; Seegert D
Expert Opin Ther Targets; 2007 May; 11(5):613-24. PubMed ID: 17465721
[TBL] [Abstract][Full Text] [Related]
17. A new model of chronic colitis in SCID mice induced by adoptive transfer of CD62L+ CD4+ T cells: insights into the regulatory role of interleukin-6 on apoptosis.
Mudter J; Wirtz S; Galle PR; Neurath MF
Pathobiology; 2002-2003; 70(3):170-6. PubMed ID: 12571422
[TBL] [Abstract][Full Text] [Related]
18. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses.
Jostock T; Müllberg J; Ozbek S; Atreya R; Blinn G; Voltz N; Fischer M; Neurath MF; Rose-John S
Eur J Biochem; 2001 Jan; 268(1):160-7. PubMed ID: 11121117
[TBL] [Abstract][Full Text] [Related]
19. Role of IL-6 and the soluble IL-6 receptor in inhibition of VCAM-1 gene expression.
Oh JW; Van Wagoner NJ; Rose-John S; Benveniste EN
J Immunol; 1998 Nov; 161(9):4992-9. PubMed ID: 9794436
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas.
Adachi Y; Aoki C; Yoshio-Hoshino N; Takayama K; Curiel DT; Nishimoto N
Int J Cancer; 2006 Sep; 119(6):1303-11. PubMed ID: 16642474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
